Skip to Main Content

When a French drug trial killed one test subject last year, many observers immediately questioned why such risks hadn’t been flagged by earlier experiments.

The drug, a potential painkiller in development by Bial, led to brain death in one case and hospitalization in five others.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!